JP2010520273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520273A5 JP2010520273A5 JP2009552583A JP2009552583A JP2010520273A5 JP 2010520273 A5 JP2010520273 A5 JP 2010520273A5 JP 2009552583 A JP2009552583 A JP 2009552583A JP 2009552583 A JP2009552583 A JP 2009552583A JP 2010520273 A5 JP2010520273 A5 JP 2010520273A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- alcohol
- hydrate
- wide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 4
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 101710017328 GSPATT00030171001 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
Claims (14)
- 結晶形態D1が、2θ = 6.8、10.8、14.8、16.2、21.8、25.1、26.1、27.2、27.8、28.5および30.4°に強度の弱いX線粉体回折ピークをさらに有する、請求項1に記載の結晶形態D1 またはその水和物。
- 結晶形態D1が、約179.6、169.1、162.5、140.0、138.0、133.8、131.9、129.6、126.0、119.2、114.7、73.6、71.2、69.9、48.0、45.5、43.2、29.0、28.6、24.2および22.2 ppmに固相13C NMRシグナルを示す、請求項1に記載の結晶形態D1またはその水和物。
- 結晶形態D2が、9.0および11.8°(w)に強度の弱いX線粉体回折ピークをさらに有する、請求項4に記載の結晶形態D2 またはその水和物。
- 結晶形態D2が、約183.3、170.3、164.0 (幅広)、138.1 (幅広)、136.0、131.7、125.7、121.8、120.2、73.0 (幅広)、44.3 (幅広)、29.1および24.6 ppmに固相13C NMRシグナルを示す、請求項4に記載の結晶形態D2 またはその水和物。
- アルコール、テトラヒドロフランおよび水を1 : 1 : 8の容量比で混合する、請求項7に記載の方法。
- アルコール、塩化メチレンおよび水を10 : 3 : 30の容量比で混合する、請求項9に記載の方法。
- 前記アルコールがC1-C6低級アルコールである、請求項7〜10のいずれか一項に記載の方法。
- 前記アルコールがメタノールである、請求項11に記載の方法。
- 請求項1〜6のいずれか一項に記載の結晶形態D1もしくはD2またはその水和物を活性成分として含んでなる、低密度リポタンパク質(LDL)のレベルを減少させるための医薬組成物。
- 低密度リポタンパク質(LDL)のレベルを減少させるための、請求項13に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070020999 | 2007-03-02 | ||
PCT/KR2008/001218 WO2008108572A1 (en) | 2007-03-02 | 2008-03-03 | Novel crystal forms of pyrrolylheptanoic acid derivatives |
KR1020080019764A KR101012917B1 (ko) | 2007-03-02 | 2008-03-03 | 피롤 헵탄산 화합물의 신규한 결정형 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010520273A JP2010520273A (ja) | 2010-06-10 |
JP2010520273A5 true JP2010520273A5 (ja) | 2012-06-14 |
Family
ID=40020978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009552583A Pending JP2010520273A (ja) | 2007-03-02 | 2008-03-03 | ピロリルヘプタン酸誘導体の新規な結晶形態 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7915302B2 (ja) |
EP (1) | EP2132171A4 (ja) |
JP (1) | JP2010520273A (ja) |
KR (1) | KR101012917B1 (ja) |
CN (1) | CN101657419A (ja) |
CA (1) | CA2679317A1 (ja) |
RU (1) | RU2421445C1 (ja) |
WO (1) | WO2008108572A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011219437A (ja) * | 2010-04-14 | 2011-11-04 | Towa Yakuhin Kk | 結晶性形態tw−1のアトルバスタチンヘミカルシウム水和物とその製造方法 |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
RU2555360C2 (ru) * | 2012-11-06 | 2015-07-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ определения воды в координационных соединениях |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
CN1423634A (zh) * | 1999-11-17 | 2003-06-11 | 特瓦制药工业有限公司 | 阿托伐他汀钙的多晶型物 |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
GEP20053546B (en) * | 2001-06-29 | 2005-06-10 | Warner Lambert Co | Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin) |
DE03713610T1 (de) | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
EP1761489A1 (en) * | 2004-03-17 | 2007-03-14 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
-
2008
- 2008-03-03 WO PCT/KR2008/001218 patent/WO2008108572A1/en active Application Filing
- 2008-03-03 CN CN200880006877A patent/CN101657419A/zh active Pending
- 2008-03-03 KR KR1020080019764A patent/KR101012917B1/ko active IP Right Grant
- 2008-03-03 US US12/449,867 patent/US7915302B2/en not_active Expired - Fee Related
- 2008-03-03 JP JP2009552583A patent/JP2010520273A/ja active Pending
- 2008-03-03 CA CA002679317A patent/CA2679317A1/en not_active Abandoned
- 2008-03-03 EP EP08723256A patent/EP2132171A4/en not_active Withdrawn
- 2008-03-03 RU RU2009136427/04A patent/RU2421445C1/ru not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010516681A5 (ja) | ||
RU2009131727A (ru) | Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения | |
JP2010533203A5 (ja) | ||
JP2009521414A5 (ja) | ||
JP2008019161A5 (ja) | ||
JP2012531408A5 (ja) | ||
JP2011121837A5 (ja) | ||
RU2015117524A (ru) | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция | |
JP2016513060A5 (ja) | ||
RU2015139042A (ru) | Способы дегидратации-гидролиза и катализаторы для них | |
JP2010520273A5 (ja) | ||
JP2012532106A5 (ja) | ||
WO2011017506A3 (en) | Synthesis and use of zsm-12 | |
RU2014104994A (ru) | Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида | |
RU2016134404A (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
RU2014104991A (ru) | Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида | |
JP6041985B2 (ja) | 結晶型t−ブチル2−[(4R,6S)−6−ホルミル−2,2−ジメチル−1,3−ジオキサン−4−イル]アセテート及びその製造方法 | |
RU2011143166A (ru) | Новые кристаллические формы адефовира дипивоксила и способы его получения | |
Cheng et al. | Study of the structures and thermal expansion properties of solid solutions Yb2− xDyxW3O12 (0≤ x≤ 1.5 and 1.8≤ x≤ 2.0) | |
RU2009136427A (ru) | Новые кристаллические формы производных пирролилгептановой кислоты | |
RU2011143805A (ru) | Кристаллы гидробромата прасугреля | |
Hu et al. | Investigation of the thermal shrink mechanism, thermal conductivity and compressive resistance of TaTiP3O12 ceramics | |
JP2011529942A5 (ja) | ||
RU2401266C2 (ru) | Гидраты солей щелочноземельных металлов и ирбесартана и их получение | |
Xu et al. | Hydrogen-Bond reorganization of a solid-state dehydration process in a salt of tris (hydroxymethyl) aminomethane and sulfosalicylic acid, investigated by powder x-ray diffraction |